絞り込み

16555

広告

日欧で低負担実現 初の大規模協力 (毎日新聞)

日本と欧州が協力して水星を調査する「ベピ・コロンボ計画」の探査機2機が19日(日本時間20日)、南米・仏領ギアナのクールー宇宙基地から欧州のアリアン5ロケットで...

  1. 変わり果てた「山水画」の世界に、中国の開...
  2. 石炭火力、保険引き受け停止相次ぐ - 日...
  3. 1-617【ミドル記事】★外国語(トルコ...
  4. 「人種差別に遺伝学使うな」米学会、白人至...

ニュース一覧

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.

著者 Iwakiri K
J Nippon Med Sch.2017 ; 84(5):209-214.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (139view , 0users)

Full Text Sources

Reflux esophagitis is characterized by excessive esophageal acid exposure. To treat reflux esophagitis, it is necessary to reduce excessive esophageal acid exposure to within the normal range. The first-line drug for the treatment of reflux esophagitis is a standard-dose proton-pump inhibitor (PPI), which is also recommended by the Evidence-based Clinical Practice Guidelines 2015 for gastroesophageal disease of the Japanese Society of Gastroenterology. It has been reported that the response to a standard dose of PPI in patients with mild reflux esophagitis is 90-100%, and that in patients with severe reflux esophagitis is 80-85%. However, PPI-resistant reflux esophagitis has been increasing. When the standard dose of PPI is not effective, modification of the lifestyle with PPI therapy, switching to another PPI, or a change in the administration method (before meals), as well as double-dose PPI (in divided doses), may be effective. In addition, vonoprazan (potassium-competitive acid blocker), which has rapid and potent acid-suppressive effects, became available in February 2015 in Japan. In the clinical trial data, vonoprazan is very effective for reflux esophagitis. However, clinical data on vonoprazan are still insufficient. The establishment of a new treatment for reflux esophagitis taking advantage of the rapid and potent acid-suppressive effects is awaited.
PMID: 29142181 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード